United Therapeutics Corporation
NASDAQ: UTHR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
United Therapeutics Corporation (UTHR) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $159.63M | $210.94M | $281.50M | $369.85M | $603.83M | $743.18M | $916.08M | $1.12B | $1.29B | $1.47B | $1.60B | $1.73B | $1.63B | $1.45B | $1.48B | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B |
| Revenue growth (YoY) | — | +32.1% | +33.4% | +31.4% | +63.3% | +23.1% | +23.3% | +21.9% | +15.4% | +13.8% | +9.1% | +7.9% | -5.7% | -11.0% | +2.4% | +13.6% | +14.9% | +20.2% | +23.6% | +10.6% |
| Cost of revenue | $17.03M | $22.26M | $30.07M | $45.32M | $73.47M | $88.90M | $119.30M | $131.13M | $125.88M | $69.04M | $72.70M | $105.70M | $198.70M | $117.60M | $108.10M | $122.50M | $146.70M | $257.50M | $309.70M | $384.40M |
| Gross profit | $142.60M | $188.68M | $251.43M | $324.53M | $530.37M | $654.28M | $796.78M | $985.86M | $1.16B | $1.40B | $1.53B | $1.62B | $1.43B | $1.33B | $1.38B | $1.56B | $1.79B | $2.07B | $2.57B | $2.80B |
| Gross margin | 89.3% | 89.4% | 89.3% | 87.7% | 87.8% | 88.0% | 87.0% | 88.3% | 90.2% | 95.3% | 95.5% | 93.9% | 87.8% | 91.9% | 92.7% | 92.7% | 92.4% | 88.9% | 89.2% | 87.9% |
| R&D | $57.57M | $83.35M | $239.18M | $122.19M | $166.76M | $180.01M | $173.39M | $299.35M | $242.55M | $245.10M | $147.60M | $264.60M | $357.90M | $1.18B | $357.70M | $540.10M | $322.90M | $408.00M | $481.00M | $550.00M |
| SG&A | $54.03M | $99.03M | $94.31M | $176.34M | $199.60M | $156.48M | $201.75M | $394.01M | $299.29M | $358.31M | $232.20M | $265.80M | $206.70M | $275.50M | $369.00M | $402.60M | $416.20M | $395.30M | $542.30M | $612.50M |
| Operating income | $28.98M | $6.30M | $-82.06M | $26.00M | $164.00M | $317.78M | $421.65M | $292.50M | $538.80M | $699.01M | $1.06B | $814.90M | $805.40M | $-187.60M | $593.60M | $555.90M | $979.70M | $1.18B | $1.38B | $1.52B |
| Operating margin | 18.2% | 3.0% | -29.1% | 7.0% | 27.2% | 42.8% | 46.0% | 26.2% | 41.8% | 47.7% | 66.4% | 47.2% | 49.5% | -12.9% | 40.0% | 33.0% | 50.6% | 50.9% | 47.9% | 47.7% |
| EBITDA | $28.98M | $22.18M | $-67.75M | $43.04M | $185.47M | $341.02M | $484.45M | $323.76M | $575.02M | $1.08B | $1.09B | $1.05B | $838.40M | $-74.90M | $646.30M | $736.80M | $1.04B | $1.39B | $1.65B | $1.82B |
| EBITDA margin | 18.2% | 10.5% | -24.1% | 11.6% | 30.7% | 45.9% | 52.9% | 29.0% | 44.6% | 73.8% | 68.2% | 61.1% | 51.5% | -5.2% | 43.6% | 43.7% | 53.7% | 59.6% | 57.5% | 57.2% |
| EBIT | $27.52M | $21.23M | $-72.28M | $31.64M | $167.55M | $320.48M | $457.31M | $292.50M | $542.77M | $1.05B | $1.06B | $1.02B | $802.50M | $-120.80M | $596.40M | $686.90M | $989.00M | $1.33B | $1.58B | $1.73B |
| Interest expense | $482000.00 | $2.17M | $16000.00 | $12.88M | $19.71M | $21.37M | $16.64M | $18.06M | $17.59M | $4.74M | $3.90M | $9.00M | $13.90M | $44.20M | $23.50M | $18.60M | $32.40M | $59.30M | $42.90M | $19.50M |
| Income tax | $-34.06M | $-3.28M | $-29.51M | $-695000.00 | $41.92M | $81.87M | $136.23M | $104.34M | $185.11M | $392.80M | $346.50M | $351.60M | $169.70M | $-60.50M | $124.10M | $118.10M | $223.30M | $289.50M | $343.90M | — |
| Effective tax rate | -85.3% | -19.8% | 40.8% | -3.7% | 28.4% | 27.3% | 30.9% | 37.4% | 35.2% | 37.6% | 32.7% | 45.7% | 22.4% | 36.7% | 19.4% | 19.9% | 23.5% | 22.7% | 22.3% | 0.0% |
| Net income | $73.97M | $19.86M | $-42.79M | $19.46M | $105.92M | $217.87M | $304.44M | $174.56M | $340.07M | $651.64M | $713.70M | $417.90M | $589.20M | $-104.50M | $514.80M | $475.80M | $727.30M | $984.80M | $1.20B | $1.33B |
| Net income growth (YoY) | — | -73.2% | -315.5% | +145.5% | +444.2% | +105.7% | +39.7% | -42.7% | +94.8% | +91.6% | +9.5% | -41.4% | +41.0% | -117.7% | +592.6% | -7.6% | +52.9% | +35.4% | +21.4% | +11.7% |
| Profit margin | 46.3% | 9.4% | -15.2% | 5.3% | 17.5% | 29.3% | 33.2% | 15.6% | 26.4% | 44.5% | 44.6% | 24.2% | 36.2% | -7.2% | 34.7% | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
Frequently asked questions
What is United Therapeutics Corporation's revenue?
United Therapeutics Corporation's trailing twelve-month revenue is $3.17B, and consensus projects about $7.85B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is UTHR?
In its most recent fiscal year, UTHR ran a gross margin of 87.92%, an operating margin of 47.67%, and a net margin of 41.94%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does UTHR generate?
UTHR produced $1.04B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is UTHR's balance sheet healthy?
UTHR holds $1.56B in cash and equivalents against — in long-term debt, on $7.10B of shareholder equity. That debt is best read against the cash flow the business throws off each year.